-+ 0.00%
-+ 0.00%
-+ 0.00%

Shareholders Can Be Confident That KOREA PHARMA's (KOSDAQ:032300) Earnings Are High Quality

Simply Wall St·11/19/2026 22:34:42
Listen to the news

Investors were underwhelmed by the solid earnings posted by KOREA PHARMA Co., Ltd. (KOSDAQ:032300) recently. We did some digging and actually think they are being unnecessarily pessimistic.

earnings-and-revenue-history
KOSDAQ:A032300 Earnings and Revenue History November 19th 2026

Zooming In On KOREA PHARMA's Earnings

In high finance, the key ratio used to measure how well a company converts reported profits into free cash flow (FCF) is the accrual ratio (from cashflow). The accrual ratio subtracts the FCF from the profit for a given period, and divides the result by the average operating assets of the company over that time. The ratio shows us how much a company's profit exceeds its FCF.

Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. While it's not a problem to have a positive accrual ratio, indicating a certain level of non-cash profits, a high accrual ratio is arguably a bad thing, because it indicates paper profits are not matched by cash flow. Notably, there is some academic evidence that suggests that a high accrual ratio is a bad sign for near-term profits, generally speaking.

Over the twelve months to September 2026, KOREA PHARMA recorded an accrual ratio of -0.11. Therefore, its statutory earnings were quite a lot less than its free cashflow. To wit, it produced free cash flow of ₩10b during the period, dwarfing its reported profit of ₩1.82b. Notably, KOREA PHARMA had negative free cash flow last year, so the ₩10b it produced this year was a welcome improvement. Importantly, we note an unusual tax situation, which we discuss below, has impacted the accruals ratio.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of KOREA PHARMA.

An Unusual Tax Situation

Moving on from the accrual ratio, we note that KOREA PHARMA profited from a tax benefit which contributed ₩521m to profit. This is of course a bit out of the ordinary, given it is more common for companies to be paying tax than receiving tax benefits! The receipt of a tax benefit is obviously a good thing, on its own. However, the devil in the detail is that these kind of benefits only impact in the year they are booked, and are often one-off in nature. In the likely event the tax benefit is not repeated, we'd expect to see its statutory profit levels drop, at least in the absence of strong growth. So while we think it's great to receive a tax benefit, it does tend to imply an increased risk that the statutory profit overstates the sustainable earnings power of the business.

Our Take On KOREA PHARMA's Profit Performance

In conclusion, KOREA PHARMA has strong cashflow relative to earnings, which indicates good quality earnings, but the tax benefit means its profit wasn't as sustainable as we'd like to see. Given the contrasting considerations, we don't have a strong view as to whether KOREA PHARMA's profits are an apt reflection of its underlying potential for profit. If you want to do dive deeper into KOREA PHARMA, you'd also look into what risks it is currently facing. Case in point: We've spotted 2 warning signs for KOREA PHARMA you should be mindful of and 1 of them is a bit concerning.

In this article we've looked at a number of factors that can impair the utility of profit numbers, as a guide to a business. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.